Abstract Multidrug resistance-associated protein 1 (MRP-1) is a ubiquitously expressed member of the ATP-binding cassette transporter family. MRP-1 is one of the primary transporters of glutathione and glutathione conjugates. This protein also transports antiretroviral therapeutics, such as HIV-1 protease inhibitors (PI). We hypothesized that inflammatory mediators that activate macrophages would modify the expression and activity of MRP-1 in macrophages. Real-time PCR assays, western blots, and calcein efflux assays were used to show that exposure of macrophage cell line RAW 264.7 to lipopolysaccharide (LPS) increased expression of MRP-1 at the levels of mRNA, protein, and functional activity. Treatment of macrophages with LPS resulted in 2-fold increases of MRP-1 expression or functional activity. LPS-mediated increases in calcein efflux were repressed by the MRP-specific inhibitor MK-571. These results suggest that the effectiveness of HIV-1 PI therapy may be compromised by the presence of opportunistic infections.
Introduction
ATP-binding cassette (ABC) transporters are a large and diverse family of proteins in which translocation of both endogenous and xenobiotic compounds is coupled to the hydrolysis of ATP. These transporters function in drug absorption, distribution, and excretion. MRP-1, which is the best characterized transporter in the ABCC family, transports organic anions. MRP-1 is expressed fairly ubiquitously in tissues such as peripheral blood mononuclear cells, kidney, brain microvascular endothelial cells, and testis (Leslie et al. 2005) . It has been demonstrated that MRP-1 transports glutathione (GSH), glutathione conjugates, and glutathione disulfide [GSSG] (Leier et al. 1996) . Glutathione is not only a substrate of MRP-1 but is also capable of modulating transport of other compounds by MRP-1 (Leslie et al. 2005) . The interactions between GSH and MRP-1 are functionally complex and not completely understood at present.
Due to its role in transport of GSH/GSSG, MRP-1 activity is a major determinant of intracellular redox status. Several independent investigations have demonstrated that MRP-1 expression is elevated in response to inducers including oxidative stress. Both γ-glutamylcysteine synthetase, the rate limiting enzyme in GSH synthesis, and MRP-1show increased expression levels in response to prooxidants such as tert-butylhydroquinone (Yamane et al. 1998) . It is of particular note that exposure to the prooxidants increased the generation of reactive oxygen intermediates (ROI). Primary cultures of rat astrocytes have also been shown to express increased levels of MRP-1 in response to exposure to the HIV-1 viral envelope protein gp120. Exposure of these cells to gp120 induced ROI as well as increased expression of MRP-1 at the levels of mRNA, protein, and functional expression (Ronaldson and Bendayan 2008) . HIV-1 Tat protein has also been demonstrated to induce MRP-1 expression in mouse brain microvascular endothelial cells (Hayashi et al. 2006) . Previous studies have demonstrated the presence of functional MRP-1 in macrophages and microglial cells (Cao et al. 1992; Dallas et al. 2004 ). Due to the pivotal role of macrophages in various infectious diseases, our laboratory has sought to determine the effects of lipopolysaccharide (LPS) on the genetic and functional expression of MRP-1. Our working hypothesis is that LPS will significantly alter the expression and function of MRP-1 in a mouse macrophage cell line. Our results demonstrate that exposure to LPS increases MRP-1 mRNA and protein, which is consistent with the increase in MRP-1 functional activity that is also observed.
Methods
Cell Line and Reagents RAW 264.7 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). The LPS (ReLPS) used was isolated from a deep rough mutant of Escherichia coli D31 m4 (Qureshi et al. 2003) . Calcein-AM was obtained from Invitrogen (Carlsbad, CA, USA). MK-571 was obtained from BIO-MOL (Plymouth Meeting, PA, USA). Calcein was purchased from Sigma (St. Louis, MO, USA). All media and serum used were obtained from Lonza (Walkersville, MD, USA).
Cell Culture RAW 264.7 macrophage-like cells were maintained in DMEM supplemented with 10% FBS and gentamycin at a concentration of 20 mg/mL. Cells were maintained in 5% CO 2 at 37°C in a humidified chamber. All experiments were performed with cells that had been passaged less than 20 times. For the isolation of RNA and protein, cells were plated at a concentration of 3×10 6 cells/ 60 mm plate. Three hours after plating, fresh media were added, containing LPS at a final concentration of 100 ng/mL. For control cells, an equivalent volume of 0.91% saline was added in place of the LPS.
RNA Isolation and Real-time PCR RNA was isolated using an RNeasyPlus Mini kit from Qiagen (Valencia, CA, USA). cDNA was generated from total RNA (1.5 μg) using MuLV reverse transcriptase and random primers (High Capacity cDNA Reverse Transcription kit; Applied Biosystems, Foster City, CA, USA). Amplification reactions were performed using TaqMan Fast Universal PCR Master Mix and TaqMan gene expression assays for either mouse MRP-1 (Mm00456156_m1) or GAPDH (Mm99999915_g1). Each amplification reaction contained cDNA generated from 10 ng of RNA and was performed using an Applied Biosystems Step One thermal cycler. Relative quantification of gene expression was performed with GAPDH as the endogenous control using the 2 ÀΔΔCt method.
Western blots For each sample, 20 μg of protein was denatured in SDS sample buffer and resolved on a 4-12% Tris-HCl polyacrylamide gels (Bio-Rad, Hercules, CA, USA). Proteins were transferred to PVDF membranes and blocked with 5% non-fat dry milk overnight. The primary antibody used to detect MRP-1 was MRPr1 (Signet Laboratories, Dedham, MA, USA). The primary antibody used to detect GAPDH (FL-335), along with appropriate species-specific secondary antibodies for the GAPDH and MRP-1 primary antibodies, was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Proteins were visualized using chemiluminescence (Pierce, Rockford, IL, USA).
Efflux experiments RAW 264.7 cells were plated in 12-well tissue culture plates at a density of 6×10 6 cells per plate and incubated under the conditions described above. After allowing cells to adhere for 3 h, the media were replaced with fresh media containing 100 ng/ml LPS. In place of LPS, an equivalent volume of 0.91% saline was added to the media in the control cells. After 20 h, the cells were washed with PBS, and DMEM (without serum or phenol red) was added to the cells. The cells were then placed in a 37°C incubator without CO 2 . At this time, MK-571 was added to the media at a final concentration of 50 mM for wells that were treated with this inhibitor. After 30 min, DMEM was replaced with DMEM containing calcein-AM at a final concentration of 5 μM or calcein-AM and MK-571. After 1 h, the DMEM containing the calcein-AM was removed, the cells were briefly washed with ice-cold PBS, and 1 mL of DMEM, or DMEM to which MK-571 had been added, was added to each well. For 1 h, 100 μL samples of media were withdrawn every 15 min for analysis; media were replaced with 100 μL of fresh media. Fluorescence of these samples was analyzed in a Bio-Tek FLx800 fluorescent plate reader (Winooski, VT, USA). The cells in each well were lysed, and protein concentration was determined using a BCA assay. The amount of calcein in the samples was quantified by comparison with standards generated by dissolving calcein in DMEM.
Results
In order to assess the effect of LPS exposure on MRP-1 expression in macrophages, RAW 264.7 cells were treated with LPS, and levels of MRP-1 mRNA, protein, and functional activity were determined. Compared to the controls, MRP-1 mRNA levels were significantly increased at 2 h after treatment (Fig. 1a) . MRP-1 mRNA levels continued to increase, so that expression reached a peak at 4-8 h that was approximately two-fold that of the control. By 12 h after LPS treatment, MRP-1 mRNA levels started to decline and by 24 h after LPS treatment, levels of MRP-1 mRNA were not significantly different from those of the control.
In terms of protein levels, western blot analyses indicated that, relative to the control, there was a decline in MRP-1 protein expression at 2 h after LPS treatment (Fig. 1b) . By 8-12 h after the initiation of LPS exposure, MRP-1 protein levels had increased so that they were significantly above the MRP-1 protein levels in the control. At 24 h post-treatment, MRP-1 protein levels in LPStreated macrophages are approximately 2-fold higher than in the control.
Efflux experiments that measured extrusion of calcein from LPS-treated macrophages were used to assess levels of MRP-1 functional activity. Efflux was measured at 20 h after the initiation of LPS treatment because elevated levels of protein expression were measured between 12 and 24 h, and preliminary experiments indicated that at this time the level of MRP-1 protein expression was at, or near, its peak. At 20 h after LPS treatment was initiated, efflux of calcein was increased by approximately 1.5-fold relative to the control (Fig. 2) . In LPS-treated cells, the MRP-1 inhibitor MK-571 suppressed calcein efflux to levels below that of the control. When control cells were exposed to MK-571, calcein efflux levels decreased to a level that was approximately 50% of the level of the control cells that were not exposed to MK-571.
Discussion
LPS treatment of RAW 264.7 cells resulted in an increase in levels of MRP-1 mRNA, protein and functional activity. The increase in mRNA was apparent after 2 h of LPS exposure, while the increase in MRP-1 at the level of protein was not evident until 8-12 h after the initiation of LPS exposure. Thus, the changes in protein levels parallel the changes in mRNA levels that were seen 4-8 h earlier. At early times after LPS exposure (2-4 h post-treatment), a transient but signifi- Total RNA was isolated from RAW 264.7 cells exposed to LPS for periods ranging between 2 and 24 h. Levels of MRP-1 RNA were determined by real-time PCR. Relative quantification of gene expression was performed with GAPDH as the endogenous control using the 2 ÀΔΔCt method. All assays were run in triplicate. The data shown are the results from three independent experiments. Asterisks indicate a statistical difference between the treatment group and the control (p<0.05) as determined by a one-way ANOVA followed by Duncan's multiple range test (b). For western blot, total protein was isolated from RAW 264.7 cells exposed to LPS for periods ranging between 2 and 24 h. Total protein (20 µg) was loaded into each well of 4-15% gradient gel and electrophoresed. The protein was transferred onto PVDF membrane and stained with commercially available antibody against MRP-1 and GAPDH. The numbers below the lane indicate the time of exposure to LPS (b) Fig. 2 LPS-mediated increase in calcein efflux. RAW 264.7 cells that had been plated in 12-well tissue culture plates were treated with LPS for 20 h and then loaded with calcein-AM for 1 h. Wells to which the MRP inhibitor MK-571 was added were pretreated with the inhibitor for 30 min before the addition of calcein-AM. After loading, cells were washed, and 1 mL of media was added to each well. At 15-min intervals, 100 μL aliquots was withdrawn and used for measuring fluorescence. At the end of 1 h, media were removed from wells, and the protein content of each well was measured using a BCA assay. Results shown are from three independent experiments. Asterisks indicate a statistical difference between the treatment group and the control (p<0.05) as determined by a one-way ANOVA followed by Duncan's multiple range test cant decrease in MRP-1 protein levels was observed. In experiments that utilized a 1-h time point after LPS exposure, a significant decrease in MRP-1mRNA level was observed. It has also been demonstrated that LPS is rapidly internalized by macrophages and stimulates increased proteolytic activity that is associated with some subunits of the proteasome (Qureshi et al. 2003) . The increase in all levels of expression relative to the control was in the range of 1.5-to 2.5-fold. It is of note that very similar results have been obtained when using the J774.1 mouse macrophage cell line (data not shown). This strongly suggests that the observed effects of LPS on MRP-1 expression are genuine rather than an artifact of the immortalized cell line.
In a previous report (Leite et al. 2007 ) MRP-1 expression in RAW 264.7 cells was studied by flow cytometry, and the results indicated that LPS caused a significant decrease in the number of RAW 264.7 cells expressing MRP-1. However, Leite et al. (2007) also suggested that LPS did cause an increase in MRP-1 functional activity because they had obtained similar results from extrusion studies on both resting and activated macrophages. Our study shows that LPS causes an increase in MRP-1expression at the levels of mRNA, protein, and functional activity.
Using mouse embryonic fibroblast cells from wild-type and knockout mice, other investigators determined that NF-E2-related fator-2 (Nrf2) is important for the expression of constitutive and inducible levels of MRP-1 (Hayashi et al. 2003) . Nrf2 is involved in the cellular response to oxidative stress by stimulating the induction of genes that are regulated by antioxidant response elements (ARE). The Nrf2 pathway has been demonstrated to regulate AREdependent pathways in macrophages and monocytes (Ishii et al. 2000; Rushworth et al. 2008) . Exposure of human monocytes to LPS induces the expression of NADPH quinone oxidoreductase and heme oxygenase 1 through the Nrf2 pathway (Rushworth et al. 2008) . This information suggests that the Nrf2 pathway is involved in the increases in MRP-1 expression that we observed.
There are important ramifications of our findings with regard to the potential impact of bacterial infection upon drug disposition, particularly in the treatment of HIV-1 infection, because the HIV-1 protease inhibitors (PI) ritonavir and saquinavir are substrates of MRP-1 (Meaden et al. 2002; Dallas et al. 2004; Eilers et al. 2008) . Attainment of effective intracellular concentrations of HIV-1 PIs in macrophages is problematic. The EC 50 value of saquinavir for inhibiting HIV-1 replication is ∼25-fold higher in chronically infected macrophages than in acutely infected lymphocytes (Perno et al. 1998) , and a similar situation occurs with ritonavir. The trough values for these antivirals fall below the EC 50 in chronically infected macrophages, a condition that is relatively ineffective at eliminating viral replication (Perno et al. 1998) . Our results suggest that the effectiveness of HIV-1 PI therapy may be compromised by the presence of opportunistic infections. A better understanding of the regulation of multidrug efflux transporters and the effects of pathogens on the expression of these transporters is necessary in order to achieve optimal therapeutic efficacy of antiretrovirals.
